Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Kristina Blegen, Sara E. Ortiz-Romero, Olivia Juarez, Julie Voeller

Research output: Contribution to journalArticlepeer-review


Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.

Original languageEnglish (US)
JournalPediatric dermatology
StateAccepted/In press - 2022


  • NF1
  • elephantiasis neuromatosa
  • neurofibromatosis
  • plexiform neurofibroma
  • selumetinib

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Dermatology


Dive into the research topics of 'Clinical impact of selumetinib on pediatric elephantiasis neuromatosa'. Together they form a unique fingerprint.

Cite this